Beam Therapeutics Inc. Revenue
Beam Therapeutics Inc. (BEAM) reported Revenue of $490.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-04
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $490.00K, a 94.21% decline year-over-year.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $31.74M, a 324.87% increase year-over-year.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $114.11M, a 279.52% increase year-over-year.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $9.70M, a 32.03% decline year-over-year.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $139.74M, a 120.01% increase from fiscal 2024.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $63.52M, a 83.18% decline from fiscal 2023.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $377.71M, a 520.01% increase from fiscal 2022.
- Beam Therapeutics Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $60.92M, a 17.51% increase from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $490.00K 10-Q · filed 2026-08-04 | $32.23M 10-Q · filed 2026-08-04 | $146.34M derived: sum of 3 quarters · filed 2026-08-04 | $156.03M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $31.74M 10-Q · filed 2026-05-07 | $145.85M derived: sum of 2 quarters · filed 2026-05-07 | $155.54M derived: sum of 3 quarters · filed 2026-05-07 | $164.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $114.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $123.81M derived: sum of 2 quarters · filed 2026-02-24 | $132.27M derived: sum of 3 quarters · filed 2026-08-04 | $139.74M 10-K · filed 2026-02-24 |
| 2025-09-30 | $9.70M 10-Q · filed 2025-11-04 | $18.16M derived: sum of 2 quarters · filed 2026-08-04 | $25.63M 10-Q · filed 2025-11-04 | $55.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $8.47M 10-Q · filed 2026-08-04 | $15.94M 10-Q · filed 2026-08-04 | $46.00M derived: sum of 3 quarters · filed 2026-08-04 | $60.27M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $7.47M 10-Q · filed 2026-05-07 | $37.54M derived: sum of 2 quarters · filed 2026-05-07 | $51.81M derived: sum of 3 quarters · filed 2026-05-07 | $63.58M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $30.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $44.34M derived: sum of 2 quarters · filed 2026-02-24 | $56.11M derived: sum of 3 quarters · filed 2026-02-24 | $63.52M 10-K · filed 2026-02-24 |
| 2024-09-30 | $14.27M 10-Q · filed 2025-11-04 | $26.04M derived: sum of 2 quarters · filed 2025-11-04 | $33.45M 10-Q · filed 2025-11-04 | $349.64M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $11.77M 10-Q · filed 2025-08-05 | $19.18M 10-Q · filed 2025-08-05 | $335.37M derived: sum of 3 quarters · filed 2026-02-24 | $352.57M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $7.41M 10-Q · filed 2025-05-06 | $323.60M derived: sum of 2 quarters · filed 2026-02-24 | $340.80M derived: sum of 3 quarters · filed 2026-02-24 | $360.91M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $316.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $333.38M derived: sum of 2 quarters · filed 2026-02-24 | $353.50M derived: sum of 3 quarters · filed 2026-02-24 | $377.71M 10-K · filed 2026-02-24 |
| 2023-09-30 | $17.19M 10-Q · filed 2024-11-05 | $37.31M derived: sum of 2 quarters · filed 2024-11-05 | $61.52M 10-Q · filed 2024-11-05 | $81.55M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $20.12M 10-Q · filed 2024-08-06 | $44.32M 10-Q · filed 2024-08-06 | $64.36M derived: sum of 3 quarters · filed 2025-02-25 | $80.16M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $24.21M 10-Q · filed 2024-05-07 | $44.24M derived: sum of 2 quarters · filed 2025-02-25 | $60.04M derived: sum of 3 quarters · filed 2025-02-25 | $76.70M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $20.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $35.84M derived: sum of 2 quarters · filed 2025-02-25 | $52.49M derived: sum of 3 quarters · filed 2025-02-25 | $60.92M 10-K · filed 2025-02-25 |
| 2022-09-30 | $15.80M 10-Q · filed 2023-11-08 | $32.45M derived: sum of 2 quarters · filed 2023-11-08 | $40.88M 10-Q · filed 2023-11-08 | $91.95M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $16.65M 10-Q · filed 2023-08-08 | $25.08M 10-Q · filed 2023-08-08 | $76.15M derived: sum of 3 quarters · filed 2024-02-27 | $76.92M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $8.43M 10-Q · filed 2023-05-10 | $59.50M derived: sum of 2 quarters · filed 2024-02-27 | $60.26M derived: sum of 3 quarters · filed 2024-02-27 | $60.27M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $51.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $51.83M derived: sum of 2 quarters · filed 2024-02-27 | $51.84M derived: sum of 3 quarters · filed 2024-02-27 | $51.84M 10-K · filed 2024-02-27 |
| 2021-09-30 | $763.00K 10-Q · filed 2022-11-07 | $769.00K derived: sum of 2 quarters · filed 2022-11-07 | $775.00K 10-Q · filed 2022-11-07 | $781.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $6.00K 10-Q · filed 2022-08-09 | $12.00K 10-Q · filed 2022-08-09 | $18.00K derived: sum of 3 quarters · filed 2023-02-28 | $24.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $6.00K 10-Q · filed 2022-05-09 | $12.00K derived: sum of 2 quarters · filed 2023-02-28 | $18.00K derived: sum of 3 quarters · filed 2023-02-28 | $24.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $12.00K derived: sum of 2 quarters · filed 2023-02-28 | $18.00K derived: sum of 3 quarters · filed 2023-02-28 | $24.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $6.00K 10-Q · filed 2021-11-08 | $12.00K derived: sum of 2 quarters · filed 2021-11-08 | $18.00K 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $6.00K 10-Q · filed 2021-08-10 | $12.00K 10-Q · filed 2021-08-10 | ||
| 2019-12-31 | $18.00K 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |